CADRENAL THERAPEUTICS INC (CVKD)

Company Profile

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 3 full-time employees. The company went IPO on 2023-01-20. The firm is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from the United States Food and Drug Administration for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). The company is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the commonly prescribed Vitamin K Antagonist (warfarin).

Company Info

CADRENAL THERAPEUTICS INC

822 A1a North, Suite 300

Ponte Vedra FLORIDA

P: 19043000701

Employees: 3

Website: https://www.cadrenal.com/